Prevalence of Hyperprolactinemia in Systemic Scleroderma (SCLERO-PRL)

University Hospital, Lille

Status: Completed

Conditions: Scleroderma; Sclerosis, Systemic; Hyperprolactinemia

Treatments: Biological: blood test

Study type: Observational

Funder types: Other

Identifiers

NCT04746313

2020-A03066-33 (Other Identifier)

2020_18

Details and patient eligibility

About

Systemic sclerosis is an autoimmune and inflammatory disease characterized primarily by fibrosis and vascular involvement. We know that the immune system is disrupted in systemic sclerosis, but there are probably other mechanisms to explain the disease, including deregulation of certain proteins such as prolactin

Enrollment: 71 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Scleroderma patients:

• man or woman over 18 years old
• with systemic sclerosis meeting ACR-EULAR 2013 criteria
• having given his no opposition
• being social insured

Healthy subjects:

• man or woman over 18 years old
• donation of blood to the EFS
• matched on age (+/- 5 years) and sex
• having given his no opposition

Exclusion criteria

• Man or woman under 18 years old
• Pregnant or breastfeeding women
• Receiving medical treatment inducing dysfunction of the hypothalamic pituitary axis
• Refusing or unable to give no objection

Trial design

71 participants in 2 patient groups

Patients with systemic sclerosis

Description:

The study will be systematically offered to any scleroderma patient seen in scheduled hospitalization

Treatment:

Biological: blood test

Healthy subjects

Description:

Healthy subjects who will donate blood to the French Blood Establishment (EFS) and matched to scleroderma patients on age (+/- 5 years) and sex

Treatment:

Biological: blood test